Edwards Lifesciences (EW) Tops Q4 EPS by 4c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
Stifel Reiterates Buy Rating on Edwards Lifesciences (EW)
February 12, 2025 1:46 PM ESTStifel analyst Rick Wise reiterated a Buy rating and $90.00 price target on Edwards Lifesciences (NYSE: EW).
The analyst comments "Edwards' 4Q24 performance checked all the critical boxes, including: (1) mid-single-digit TAVR growth (5.3%), despite a 12.1% 4Q23 comp and selling day headwind, suggests that TAVR growth... More



